Lactobacillus compositions and uses thereof
Through the treatment of Lactobacillus strains, the problem of elevated biochemical and physiological indicators under acute psychosocial stress was solved, which significantly reduced the levels of soluble fractalkine and CD163, improved health status, and provided effective prevention of diseases related to acute psychosocial stress and treat.
Patent Information
- Application Number
- CN202411289534.0
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Priority Date
- 2019-06-07
- Filing Date
- 2020-06-05
- Publication Date
- 2024-11-08
AI Technical Summary
The prior art is difficult to effectively reduce and prevent the harmful effects of acute psychosocial stress in humans. Especially in individuals with chronic stress, biochemical and physiological indicators such as soluble fractalkine and CD163 levels caused by acute psychosocial stress affect health.
Treatment with at least one Lactobacillus strain by administering an effective dose of Lactobacillus strain, reducing and preventing the harmful effects of acute psychosocial stress, including reducing soluble fractalkine and CD163 levels in plasma, improving physiological indicators such as pulse, heart rate and intestine 联分类.
Through the use of Lactobacillus strains, the soluble fractalkine and CD163 levels in plasma under acute psychosocial stress are significantly reduced, related symptoms and diseases are alleviated, and prevention and treatment effects on diseases related to acute psychosocial stress.
Smart Images

Figure CN118903221A_ABST
Abstract
Description
[0001] This application is a divisional application of the Chinese patent application with application number 202080041840.6, application date June 5, 2020, and invention name “Lactobacillus compositions and uses thereof”. Technical Field
[0002] The present invention relates to at least one Lactobacillus strain for use in a method for reducing and / or preventing at least one detrimental effect of acute psychosocial stress in humans, wherein the method comprises treatment by administering an effective dose of at least one Lactobacillus strain, preferably wherein the at least one detrimental effect is an increased level of soluble fractalkine, optionally in combination with at least one further detrimental effect of acute psychosocial stress. Background Art
[0003] Stress is the response of an organism to a stressor, such as an environmental condition. Stress involves the way the body responds to a threat, challenge, or condition such as a physical or psychological disorder. These conditions, threats, challenges, or disorders are called stressors. The autonomic nervous system and the hypothalamic-pituitary-adrenal (HPA) axis are two major systems that respond to stress.
[0004] The sympathetic adrenal medullary (SAM) axis activates the fight-or-flight response through the sympathetic nervous system, while the parasympathetic nervous system restores the body to homeostasis. The HPA axis regulates the release of cortisol, which affects many body functions, such as metabolic, psychological, and immune function. The SAM and HPA axes are regulated by several brain regions, including the limbic system, prefrontal cortex, amygdala, hypothalamus, and striatum.
[0005] Acute stress can overactivate the immune system, leading to an imbalance between inflammation and anti-inflammation. By disrupting the balance of the immune system, stress can induce peripheral and central inflammation. This imbalance leads to a variety of stress-related diseases such as cardiovascular disease, neurodegenerative diseases, and cancer (Liu et al., 2017, Front Hum Neurosci; 11: 316).
[0006] Stress also increases the gastrointestinal system’s response to inflammation and may reactivate prior inflammation and accelerate the inflammatory process (Yaribeygi et al., 2017, EXCLI J. 16:1057–1072). For example, chronic stress may increase the risk of inflammatory bowel disease (IBD), and acute psychosocial stress may exacerbate this risk. Irritable bowel syndrome may be caused in part by inflammation and is also associated with stress.
[0007] Therefore, there is a need in the art to find effective methods to reduce and / or prevent the deleterious effects of acute psychosocial stress in humans, particularly in individuals who also suffer from chronic stress. Summary of the invention
[0008] The present invention provides at least one Lactobacillus strain for use in a method for reducing and / or preventing at least one harmful effect of acute psychosocial stress in humans, wherein the method comprises treating by administering an effective dose of the at least one strain. According to the present invention, administering the at least one Lactobacillus strain preferably reduces and / or prevents at least one harmful effect of acute psychosocial stress in humans compared to the at least one harmful effect of acute psychosocial stress in humans in the absence of the at least one strain.
[0009] In a first aspect, administration of at least one Lactobacillus strain reduces and / or prevents elevated levels of soluble fractalkine as a deleterious effect of acute psychosocial stress.
[0010] In a second aspect, the administration of at least one lactobacillus strain reduces and / or prevents elevated levels of soluble fractalkine as a deleterious effect of acute psychosocial stress, in combination with reducing or preventing at least one further deleterious effect of acute psychosocial stress. At least one further deleterious effect may be selected from biochemical and / or physiological markers. At least one further deleterious effect may be elevated levels of soluble CD163.
[0011] In a third aspect, administration of at least one Lactobacillus strain reduces and / or prevents elevated levels of soluble CD163 as a deleterious effect of acute psychosocial stress.Administration may reduce or prevent one or more further deleterious effects of acute psychosocial stress.
[0012] In a fourth aspect, the administration of the at least one Lactobacillus strain reduces and / or prevents at least one adverse effect of psychosocial stress, wherein the adverse effect is a physiological indicator. The physiological indicator may be selected from an increased pulse, an increased heart rate, an increased high frequency heart rate variability, an increased intestinal permeability and an adverse intestinal function, such as increased abdominal pain, flatulence and / or bloating.
[0013] "For reducing and / or preventing" includes the meaning of such uses: it has the effect of preventing, delaying, preventing, alleviating and / or eliminating the severity of one or more effects, symptoms and / or other markers associated with a disorder, disease or condition on a subject. "Prevent", "prevention" or "preventing" include the meaning that the event, effect or condition being prevented is prevented, delayed, alleviated (e.g., reduced in severity), prevented from occurring or stopped. Such prevention usually occurs before the event occurs or the effect or condition manifests, but it should be understood that this also means preventing further events of the same type from occurring. It should also be understood that such terms can include the meaning that the event or condition remains in its current state and does not get worse or develop further.
[0014] For example, following administration of at least one strain (or a composition comprising at least one strain) according to the present invention, measurements of biochemical markers of stress (e.g., soluble fractalkine) associated with or preceding acute psychosocial stress may be reduced by at least 0.5%, 1%, 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98% or at least 99% compared to not administering the at least one strain, or compared to administering a corresponding composition lacking the at least one strain.
[0015] "Psychosocial stress" includes the meaning of stress caused by socially threatening situations, which can include social evaluation, social rejection, and 'achievement' situations that claim goal-directed performance (see Kogler et al., 2015, Neuroimage 119:235-251, which is incorporated herein by reference in its entirety). Psychosocial stress can arise from situations in which the need to meet the need to associate with others and / or the need to maintain a social self is threatened. 'Achievement situations' are situations in which an individual believes that his or her performance will be evaluated. Thus, psychosocial stress includes stress caused by situations in which an individual's performance may be negatively evaluated by others.
[0016] It should be understood that the term "psychosocial stress" includes the effects induced by specific psychosocial stressors. Thus, psychosocial stressors include the possibility of negative judgments from others about one's performance, particularly where such judgments may lead to social exclusion or lack of achievement.
[0017] It should be understood that psychosocial stress is intended to exclude physiological stress. "Physiological stress" includes the meaning of stress associated with potential damage to body tissues and physical threats, such as pain, hunger, oxidative stress, etc. (see Kogler et al., 2015, supra). It should also be understood that psychosocial stress is intended to exclude stress caused by physical activity or exercise, such as described in WO 00 / 70972, and any stress caused by infection or allergy. Physiological stress triggers the 'fight or flight' response, while during psychosocial stress, attention is turned to emotion regulation and goal-oriented behavior, and reward processing is reduced (Kogler et al., 2015, supra).
[0018] By "acute" in the context of "acute psychosocial stress" we include the meaning that the presence of a stressor and / or the stress response to the stressor is limited in time. Thus, acute stressors typically involve short-term challenges. For example, an acute stressor (and / or the stress response to that stressor) typically exists for less than a day, such as no more than 12, 11, 10, 9, 8, 7 hours, or preferably less than 6, 5, 4, 3, 2, or 1 hour. It should be understood that more than one acute psychosocial stressor may occur in a day, and the same or similar acute stressor may cause more than one acute psychosocial stressor within a short period of time (e.g., within a 24 to 72 hour period) and still be considered to cause acute stress.
[0019] Examples of acute psychosocial stressors (or stimuli that cause acute psychosocial stress) include, but are not limited to, situations such as: having a meeting; giving an oral presentation or speech; taking an exam; making an important phone call; attending an important meeting; having to work by a deadline (or close to an imminent deadline); being bullied; receiving unexpected serious news, such as illness, bereavement, or job loss. It should be understood that the term "acute" is intended to generally exclude the meaning of the term "chronic." By "chronic" we include the meaning of a persistent state. It should be understood that a persistent state can include fluctuations and not just a static state. In contrast to the limited time frame of "acute," situations for "chronic" typically require repetition or duration of several days, preferably more than 1, 2, 3, 4, 5 or 6 weeks or more than 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11 or 12 months.
[0020] By "chronic stress" we include the meaning of ongoing stress states. Chronic stress generally involves responses to emotional stress experienced over a long period of time, over which the individual perceives they have little or no control. Examples of chronic stress states are those following severe life events, such as periods of bereavement, unemployment, loneliness, or ongoing marital problems.
[0021] It is also understood that acute stressful events may precede or lead to periods of chronic stress. For example, an acute stressor may be the receipt of unexpected serious news (e.g., illness, bereavement, or job loss), while a chronic stressor may be the persistence of a negative situation that is the subject of the news (e.g., illness, bereavement, or job loss).
[0022] “Effects of acute psychosocial stress” includes the meaning of physical measures that are directly or indirectly caused by the presence of acute psychosocial stress. “Harmful” includes the meaning of causing harm or damage. Thus, by “harmful effects of acute psychosocial stress,” we include the meaning that acute psychosocial stress may cause, worsen, or exacerbate specific measures of harm or damage to an individual.
[0023] Preferably, the deleterious effects of acute psychosocial stress are selected from one or more biochemical and / or physiological indicators of stress. It is understood that the deleterious effects of acute psychosocial stress may be manifested (e.g., measurable) before, during, or after the onset of acute psychosocial stress. Preferably, the deleterious effects of acute psychosocial stress are measurable within one hour during and / or after the onset of acute psychosocial stress.
[0024] Examples of biochemical indicators of stress include elevated levels of cytokines, particularly inflammatory cytokines and / or zonulin and / or Cortisol and / or soluble CD 163. Preferably, the inflammatory cytokine is one or more soluble fractalkine (chemokine [C-X3-C motif] ligand 1, encoded in humans by the CX3CL1 gene). C-reactive protein (CRP, encoded in humans by the CRP gene), interferon gamma (IFNγ, encoded in humans by the IFNG gene), interleukin 10 (IL-10 or human cytokine synthesis inhibitor [CSID], encoded in humans by the IL10 gene), interleukin 1 beta (IL-1β, encoded in humans by the IL1B gene), interleukin 6 (IL-6, encoded in humans by the IL6 gene), interleukin 8 (IL-8 or chemokine [CXC motif] ligand 8, CXCL8, encoded in humans by the CXCL8 gene), or tumor necrosis factor alpha (TNFα, cachexin or cachectin, encoded in humans by the TNFA gene). Zonulin, also known as haptoglobin 2 precursor (uncleaved form of allele α-2 [2-2]), is a protein encoded by the human HP gene (see Fasano, 2011, Physiol Rev, 91(1): 151-175, the entire contents of which are incorporated herein by reference) and regulates the permeability of tight junctions between cells of the digestive tract wall. Zonulin is considered to be the mammalian analog of the zonula occludens toxin secreted by Vibrio cholerae, and therefore, zonulin has been implicated in the pathogenesis of celiac disease and type 1 diabetes. Cortisol, also known as hydrocortisone, is a steroid hormone in the glucocorticoid class of hormones that is primarily produced in the adrenal cortex within the adrenal glands, but there is also evidence that it is synthesized locally in the intestine (see Taves et al., 2011, Am J Physiol Endocrinal Metab, 301(1): E11-E24, the entire contents of which are incorporated herein by reference). CD163 (encoded by the CD163 gene in humans) is a scavenger receptor that belongs to the scavenger receptor cysteine-rich family type B. Membrane-bound CD163 has an extracellular domain of 1048 amino acid residues, a single transmembrane segment, and a cytoplasmic tail with multiple splice variants. Soluble CD163 (sCD163) is produced by shedding of the membrane-bound receptor extracellular domain by enzymatic cleavage by ADAM17, also known as tumor necrosis factor-α converting enzyme (TACE). sCD163 is present in plasma and cerebrospinal fluid. sCD163 is upregulated in a variety of inflammatory diseases, including cirrhosis, type 2 diabetes, macrophage activation syndrome, Gaucher disease, sepsis, HIV infection, rheumatoid arthritis, and Hodgkin lymphoma. sCD163 is also upregulated in cerebrospinal fluid after subarachnoid hemorrhage.
[0025] Biochemical markers of stress can be determined by any suitable measure known in the art. Preferably, biochemical markers of stress are measured in plasma or serum. For example, the levels of cytokines (including chemokines), peptides or proteins can be measured by enzyme-linked immunosorbent assay (ELISA) with antibodies specific for the cytokine to be measured, or by multiplex kits from MesoScale Discovery of Rockville, Maryland, USA. Techniques for measuring hormones (e.g., Cortisol) include immunoassays (e.g., ELISA) and liquid chromatography tandem mass spectrometry (LC-MS / MS). It should also be understood that biochemical markers of stress can be measured in other biological samples, such as urine, feces, saliva, breath, tears, lymph, cerebrospinal fluid, synovial fluid, or tissue biopsy.
[0026] Examples of physiological indicators of stress include increased pulse, increased heart rate, increased high frequency heart rate variability, increased intestinal permeability, and adverse intestinal function, such as increased abdominal pain, gas, and / or bloating.
[0027] Physiological indicators of stress can be determined by any suitable measure known in the art. For example, a measurement of heart rate can be determined by an electrocardiogram, and a measurement of bowel function can be determined by a questionnaire with a visual analog scale.
[0028] In a most preferred embodiment, the biochemical marker of stress is elevated levels of soluble fractalkine, preferably elevated levels of soluble fractalkine in plasma.
[0029] Therefore, in a preferred embodiment according to the present invention, at least one Lactobacillus strain is used in a method for reducing and / or preventing increased levels of soluble fractalkine in plasma as a deleterious effect of acute psychosocial stress in humans, wherein the method comprises treatment by administering an effective dose of at least one Lactobacillus strain.
[0030] Fractalkine
[0031] Fractalkine is the only known member of the CX3 C chemokine family, characterized by having three amino acids separating the cysteine near the N-terminus. In mice, fractalkine is also known as neurotactin. Membrane-bound fractalkine (CX3CL1) has 373 amino acids (human mature length after removal of the signal peptide), which includes the N-terminal domain (residues 1-76), the mucin-like stem (residues 77-317), the transmembrane alpha helix (residues 318-336) and the cytoplasmic tail (residues 337-373) (Jones et al., 2010, Mol Interv, 10(5):263-70; Bazan et al., 1997, Nature, 385:(6617):640-644; both of which are incorporated herein by reference in their entirety).
[0032] The main sites of fractalkine expression are neurons and epithelial cells in the lungs, kidneys and intestines. Endothelial cells and smooth muscle cells under inflammatory conditions can also express fractalkine (White et al., 2012, supra). Membrane-bound fractalkine expressed on activated endothelial cells promotes strong adhesion of leukocytes. Fractalkine interacts with chemokine receptor CX3CR1 (e.g., on the surface of NK cells, cytotoxic T lymphocytes and γ-δ cells) to trigger its adhesion and migration functions. Under inflammatory conditions, membrane-anchored fractalkine is also expressed on monocytes, indicating that fractalkine plays a role in inflammatory diseases (Jones et al., 2010, supra). It has been found that membrane-anchored fractalkine expressed on neurons is essential for microglial migration because microglial cells express CX3CR1 receptors. Fractalkine is also upregulated in the hippocampus during a short time window after spatial learning.
[0033] The soluble 95kDa form of fractalkine (soluble fractalkine or processed fractalkine) contains a chemokine domain and an extracellular mucin-like stem. Soluble fractalkine is released by cleaving membrane-bound fractalkine at the base of the mucin stem by the shedding protease ADAM10 or ADAM17 (Zunke et al., 2017, BiochimBiophys Acta Mol Cell Res, 1864(11Pt B): 2059-2070). The shedding of ADAM10 is considered to be constitutive, while the shedding of ADAM17 is a response to cell activation, such as in inflammatory conditions (White et al., 2012, supra). At least two cleavage sites of ADAM10 are known (White et al., 2012, Arterioscler Thromb Vasc Biol, 32: 589-594). Soluble fractalkine effectively chemically attracts T cells, monocytes and natural killer (NK) cells.
[0034] The amount of fractalkine and its receptor CX3CR1 has been shown to be increased in various forms of cancer, inflammatory diseases and cardiovascular diseases. For example, it has been reported that soluble fractalkine levels are increased in patients with coronary artery plaque rupture (Ikejima et al., 2010, Circ J, 74: 337-345) and fractalkine is associated with cardiovascular disease through its proliferation and anti-apoptotic effects on primary human smooth muscle cells (White et al., 2010, Cardiovasc Res, 85: 825-835). Increased levels of soluble fractalkine have also been reported in the synovial fluid of rheumatoid arthritis (Ruth et al., 2001, Arthritis Rheum, 44: 1568-1581). Intestinal epithelial cells expressing membrane-anchored fractalkine have been shown to shed soluble fractalkine in response to stimulation with IL-1β (Muehlhoefer et al., 2000, J Immunol, 164: 3368-3376). Furthermore, human intestinal microvascular endothelial cells have been shown to release soluble fractalkine in response to combined IFN-γ and TNFα stimulation, but not to stimulation with IFN-γ or TNFα alone, with levels being higher in cells from patients with ulcerative colitis and Crohn's disease than in healthy controls (Sans et al., 2007, Gastroenterology, 132(1):139-53).
[0035] Administration of anti-fractalkine monoclonal antibodies in two mouse models of inflammatory bowel disease showed positive results, including inhibition of weight loss, suggesting a role for fractalkine in the pathogenesis of IBD (Nishimura et al., 2009, Ann NY Acad Sci, 1173:350-6). Nishimura et al., 2009 highlighted the biological significance of the fractalkine-fractalkine receptor (CX3CL1-CX3CR1) interaction in the development of colitis.
[0036] The colon of patients with inflammatory bowel disease shows elevated levels of fractalkine and a large number of fractalkine receptor-positive cells. Mice injected with anti-fractalkine monoclonal antibodies to disrupt the fractalkine-fractalkine receptor pathway effectively inhibited intravascular monocyte patrolling behavior; reduced the expression of inflammatory cytokines in the colon; maintained vascular integrity and significantly suppressed colitis symptoms in the oxa-induced mouse colitis model (Kuboi et al., 2019, Int Immunol. 2019Apr26;31(5):287-302). Anti-fractalkine antibodies also improved the symptoms of another IBD model, T cell transfer colitis. The results of Kuboi et al., 2019 indicate that the fractalkine-fractalkine receptor axis plays a key role in the pathogenesis of the murine colitis model and suggest that disrupting the fractalkine-fractalkine receptor interaction and related pathways may be an effective strategy for treating inflammatory bowel disease (IBD), including Crohn's disease (CD) and ulcerative colitis (UC).
[0037] Fractalkine and its receptor play a role in chemotherapy-induced peripheral neuropathy (CIPN). When fractalkine and fractalkine receptors are highly expressed, they activate spinal microglia, which then produce inflammatory factors such as TNF-α and IL-1b through the P38 / MAPK signaling pathway, leading to CIPN (Clark and Malcangio, 2012, Exp Neurol. 2012 Apr; 234 (2): 283-92). Gastrodin inhibits the activation of spinal microglia by reducing fractalkine and fractalkine receptor pathways, thereby alleviating CIPN induced in mice (Qin et al., Drug Chem Toxicol. 2018 Dec 17: 1-8).
[0038] The pathophysiological mechanisms of diabetic retinopathy (DR) are complex and may be closely related to and possibly associated with oxidative stress, NF-κB, and inflammatory mediators. The expression of various oxidative stress and inflammatory mediators, including fractalkine, was assessed in diabetes-induced rats using RT-PCR, Western blot analysis, and enzyme-linked immunosorbent assay (ELISA). Some of the rats were treated with cilostazol. In the retinas of diabetic rats, fractalkine mRNA levels were increased fivefold, while fractalkine expression was increased fourfold in diabetic mice compared with healthy rats. Treatment with cilostazol reduced the level of fractalkine mRNA by 66% and fractalkine expression by 62%. Monitoring other markers of oxidative stress and inflammation revealed that cilostazol reduced inflammatory responses and oxidative stress in diabetic eyes. The anti-inflammatory effects of cilostazol may be achieved indirectly by reducing oxidative stress, inhibiting NF-κB activity, and subsequently reducing inflammatory mediators. Cilostazol may be beneficial in preventing the progression of diabetic retinopathy through these mechanisms (Yeh et al., Curr Eye Res 2019 Mar; 44(3): 294-302). Therefore, it should be understood that the reduction of soluble fractalkine may be beneficial in providing protection and / or treatment for conditions or diseases in which elevated soluble fractalkine is involved. However, prior to the present disclosure, no link had been established between acute psychosocial stress and fractalkine release.
[0039] In a most preferred embodiment, administration of at least one strain according to the present invention can reduce or prevent increased levels of soluble fractalkine in plasma as a deleterious effect of acute psychosocial stress in humans, thereby providing protection and / or relief from disorders, conditions or diseases associated with increased soluble fractalkine, such as cancer, chemotherapy-induced peripheral neuropathy (CIPN), diabetic retinopathy (DR), inflammatory diseases, cardiovascular diseases, inflammatory bowel disease (IBD), irritable bowel syndrome (IBS), ulcerative colitis and Crohn's disease.
[0040] Patient Group
[0041] It will be appreciated that at least one strain according to the invention may be used to reduce and / or prevent at least one detrimental effect of acute psychosocial stress in any person experiencing acute psychosocial stress.
[0042] In particular, at least one strain is suitable for use in humans (male and / or female), including adolescents (12-17 years), young adults (18-30 years), and adults over 30, 40, 50, 60, 70 and 80 years of age.
[0043] The person to be treated may be an individual suffering from chronic stress or an individual not suffering from chronic stress.
[0044] "Chronic stress" includes a score of 3.75 or higher on the Shirom-Melamed Burnout Questionnaire (SMBQ) (Grossi et al., 2003, J Psychosomatic Res 55:309-316). Thus, a person to be treated may have chronic stress, which is indicated by a score of 3.75 or higher on the SMBQ. Alternatively, a person to be treated may not have chronic stress, which is indicated by a score below 3.75 on the SMBQ.
[0045] It should also be understood that "chronic stress" is not intended to include depression. Depression includes a score of 45 or higher on the Zung Self-Rating Depression Scale (Zung, 1965, Arch Gen Psychiatry, 12:63-70, the entire contents of which are incorporated herein by reference).
[0046] Lactobacillus strains
[0047] The at least one lactobacillus strain according to the invention may be alive, inactivated or dead. Preferably, the strain is alive. For example, the strain is preferably freeze-dried.
[0048] Advantageously, at least one Lactobacillus strain is a probiotic strain.
[0049] Probiotics are defined as "live microorganisms that confer a health benefit on the host when administered in adequate amounts" (Hill et al., Nat Rev Gastroenterol Hepatol, 2014, 11(8):506-514). In order for a bacterium to meet the definition of a probiotic, it must generally be able to survive and colonize the intestine, survive the manufacturing and storage processes, and have evidence of a positive effect on consumer health.
[0050] "At least one probiotic strain" includes the meaning of one or more bacterial strains that, when administered in sufficient amounts, confer a health benefit on the host. Preferably, "at least one strain" according to the first aspect of the present invention may be selected from the group consisting of Lactobacillus plantarum, Lactobacillus paracasei, Lactobacillus rhamnosus, Lactobacillus crispatus, Lactobacillus gasseri, Lactobacillus fermentum, Lactobacillus reuteri, Lactobacillus acidophilus, Lactobacillus helveticus, Lactobacillus casei, Lactobacillus salivarius and Lactobacillus johnsonii.
[0051] Preferably, the "at least one strain" according to the present invention is at least one strain of Lactobacillus plantarum.
[0052] Preferably, the at least one strain of Lactobacillus plantarum is selected from Lactobacillus plantarum DSM 15312 (HEAL 9 TM ), Lactobacillus plantarum DSM 15313 (HEAL 19 TM ), Lactobacillus plantarum DSM 15316 (HEAL 99 TM )、Lactobacillus plantarum DSM6595(299 TM ), Lactobacillus plantarum DSM 9843 Lactobacillus plantarum DSM 32131 (GOS42 TM ), Lactobacillus plantarum DSM 17852 (LB3e TM ) and Lactobacillus plantarum DSM 17853 (LB7c TM ).
[0053] Lactobacillus plantarum DSM 15312 (HEAL 9 TM ), Lactobacillus plantarum DSM 15313 (HEAL 19 TM ) and Lactobacillus plantarum DSM 15316 (HEAL 99 TM) was deposited by Probi on November 27, 2002 at DSMZ-DEUTSCHE SAMMLUNG VON MIKROORGANISMEN UND ZELLKULTUREN GmbH, Mascheroder Weg1b, D-38124 Braunschweig, Germany.
[0054] Lactobacillus plantarum DSM 6595 (299 TM ) was deposited on July 2, 1991 in the name of Probi (i.e., Probi AG) with DSM-DEUTSCHE SAMMLUNG VONMIKROORGANISMEN UND ZELLKULTUREN GmbH, Mascheroder Weg 1B, D-3300 Braunschweig, Germany.
[0055] Lactobacillus plantarum DSM 9843 Deposited by Probi on March 16, 1995 at DSM-DEUTSCHE SAMMLUNG VONMIKROORGANISMEN UND ZELLKULTUREN GmbH, Mascheroder Weg 1b, D-38124 Braunschweig, Germany.
[0056] Lactobacillus plantarum DSM 32131 (GOS42 TM ) was deposited by Probi on September 2, 2015 at the Leibniz Institute DSMZ-German Collection of Microorganisms and Cell Cultures, Inhoffenstr. 7B, D-38124 Braunschweig, Germany.
[0057] Lactobacillus plantarum DSM 17852 (LB3e TM ) and Lactobacillus plantarum DSM 17853 (LB7c TM ) was deposited by Probac AB at DSMZ-Deutsche Sammlung von Mikroorganismen und Zellkulturen GmbH, Mascheroder Weg 1b, D-38124 Braunschweig, Germany on January 6, 2006. Subsequently, all rights and obligations related to the microbial deposits DSM 17852 and DSM 17853 were assigned to Probac AB, which has now become the depositary of the DSM 17852 and DSM 17853 strains.
[0058] Preferably, at least one strain of Lactobacillus plantarum is capable of adhering to the intestinal epithelium and persisting in the intestine. Certain strains of this species contain mannose-specific adhesins (Adlerberth et al., 1996, Appl Environ Microbiol, 62(7):2244-2251, the entire contents of which are incorporated herein by reference), including Lactobacillus plantarum DSM 15312 (HEAL 9 TM ), Lactobacillus plantarum DSM 15316 (HEAL 99 TM ), Lactobacillus plantarum DSM 9843 and Lactobacillus plantarum DSM 6595 (299 TM ).
[0059] Most preferably, the at least one strain of Lactobacillus plantarum is Lactobacillus plantarum DSM 15312 (HEAL 9 TM ).
[0060] Composition
[0061] At least one strain according to the present invention may be present in a composition comprising at least one suitable carrier. For example, the carrier may be a diluent or an excipient. The composition may be in the form of a solid or liquid formulation, and thus the at least one carrier may be solid or liquid or may include both at least one solid component and at least one liquid component.
[0062] Examples of suitable liquid carriers include water, milk, coconut water, fruit drinks and juices, milk alternatives (soy drinks, oat drinks, nut and other plant-based drinks), sparkling drinks, oil preparations (including one or more of nut oils or vegetable oils, such as coconut, rapeseed, olive, corn / maize); palm; glycerin, propylene glycol and other aqueous solvents.
[0063] Examples of suitable solid carriers or excipients include maltodextrin, inulin, cellulose (such as microcrystalline cellulose (MCC), hydroxypropylmethylcellulose (HPMC) or hydroxypropylcellulose (HPC)), sugar alcohols, high molecular weight polyethylene glycols, lactose, sodium citrate, calcium carbonate, calcium hydrogen phosphate and glycine, disintegrants (such as starch (preferably corn, potato, cassava or other plant starch), sodium starch glycolate, cross-linked sodium carboxymethylcellulose and certain complex silicates) and granulation binders (such as polyvinyl pyrrolidone, sucrose, gelatin and gum arabic). In addition, lubricants such as magnesium stearate, stearic acid, glyceryl behenate and talc may be included.
[0064] In an embodiment according to the first aspect of the present invention, the carrier may be selected from pharmaceutically and / or nutritionally (food grade) acceptable carriers or excipients. For example, the carrier material may be a food.
[0065] Examples of suitable pharmaceutically acceptable carriers, excipients and diluents include those well known to those skilled in the art, such as those given in Remington: The Science and Practice of Pharmacy, 19th Edition, Vols. 1 and 2 (ed. Gennaro, 1995, Mack Publishing Company).
[0066] “Food grade” includes carriers, ingredients and excipients that meet “Generally Recognized As Safe” (GRAS) standards.
[0067] "Food" includes any edible substance that provides nutrition or support to an organism. Examples of suitable food carriers include beverages (e.g., juices), dairy products (e.g., yogurt, cheese, ice cream, infant formula and spreads such as margarine), dairy alternative products (e.g., soy, nut or other plant-based beverages, yogurts and spreads), grain-based products (e.g., bread, biscuits, breakfast cereals, pasta and dry food bars (e.g., health bars)) and baby foods (e.g., fruit purees and / or vegetable purees).
[0068] Compositions according to the present invention can be dry non-fermented compositions, fermented compositions or dry fermented compositions. In this context, fermentation is specifically included in lactic acid fermentation by lactobacillus under anaerobic conditions. In the case of dry non-fermented compositions, fermentation does not occur substantially before the subject takes in, and therefore fermentation is only carried out in the gastrointestinal tract after the subject takes in the composition.
[0069] Thus, in some embodiments according to the present invention, the composition is in the form of a food product, wherein the food product is a cereal-based product, a dairy product, a fruit drink or a fermented food.
[0070] Examples of fermented foods include fermented dairy products (such as yogurt, kefir or lassi), dairy-free fermented dairy alternatives (such as coconut milk kefir), fermented grain-based products (such as oats, oatmeal, corn, sorghum, wheat), fermented vegetables (such as sauerkraut, kimchi or pickles), fermented beans or soy (such as natto or tempeh), and fermented teas (such as kombucha). Other examples of dairy-free milk alternatives include almond, soy and oat-based "ghurts".
[0071] In some embodiments according to the present invention, the at least one strain is present in a non-naturally occurring composition, for example, the composition includes more than just a probiotic strain and water.
[0072] In use, before being applied to mammals, at least one bacterial strain according to the present invention or a composition comprising at least one bacterial strain can be mixed with a liquid or solid carrier. For example, the subject can mix at least one bacterial strain or its composition with a carrier comprising one or more liquids before taking in, and the one or more liquids are selected from water, milk, coconut water, fruit drinks and juices, milk substitutes (soy beverages, oat beverages, nuts and other beverages based on plants), sparkling beverages or some other aqueous solvents or beverages. Similarly, at least one bacterial strain or its composition can be mixed with a carrier consisting of one or more foods. Suitable food carriers include oatmeal carriers, barley carriers, fermented or non-fermented dairy products, such as yogurt, ice cream, milk shakes, juices, beverages, soups, bread, biscuits, pasta, breakfast cereals, dry food bars (comprising health bars), plant-based foods (such as soy products), spreads, baby food, infant nutrition, infant formula, breast milk substitutes at birth.
[0073] Preferably, the formulation is a unit dose containing a daily dose or unit, daily sub-dose, or an appropriate fraction thereof, of a composition comprising the strain.
[0074] The composition according to the present invention may be a dietary supplement. "Dietary supplement" includes the meaning of a manufactured product intended to supplement the diet by oral consumption, such as a pill, capsule, tablet or liquid. A dietary supplement may contain substances essential to life and / or substances that have not yet been proven to be essential to life, but may have beneficial biological effects. When the composition according to the present invention is in the form of a dietary supplement, the carrier to be added includes those known to those skilled in the art, such as those described in Remington: The Science and Practice of Pharmacy, 19 th Those given in , ed., vol. 1 & 2 (ed. Gennaro, 1995, Mack Publishing Company). Any other ingredients commonly used in dietary supplements are known to the skilled person and may also be routinely added together with the at least one strain.
[0075] The composition according to the present invention may be provided in the form of a solution, a suspension, an emulsion, a tablet, a granule, a powder, a capsule, a lozenge, a chewing gum or a suppository.
[0076] For example, in a preferred embodiment, the composition according to the invention is a dietary supplement in the form of capsules comprising freeze-dried lactobacilli.
[0077] In an embodiment according to the present invention, the at least one strain is present in an amount of about 1×10 6 To about 1×10 14 CFU / dose, preferably about 1×10 8 To about 1×10 12 CFU / dose, more preferably about 1×10 9 To about 1×10 11 CFU / dose, and most preferably about 1×10 10 CFU / dose. If the at least one strain consists of more than one strain, this amount represents the total CFU / dose of the combination of strains. For example, the at least one strain may be present in an amount of about 1×10 6 , 1×10 7 , 1×10 8 , 1×10 9 , 1×10 10 , 1×10 11 , 1×10 12 or about 1×10 13 CFU / dose. The at least one strain may be present in an amount of about 1×10 14 , 1×10 13 , 1×10 12 , 1×10 11 , 1×10 10 , 1×10 9 , 1×10 8 or about 1×10 7 The at least one strain according to the invention may also be used alone in water or any other aqueous vehicle to which the at least one strain is added or mixed prior to ingestion.
[0078] The composition according to the present invention can be administered orally, buccally or sublingually in the form of tablets, capsules, powders, beads, elixirs, solutions or suspensions, which may contain flavoring agents or coloring agents for immediate release, delayed release or controlled release applications. The composition can be administered in the form of a powder composition, such as a fast-dissolving microbial composition, for example, in WO 2017 / 060477 or in the UK patent application No. 1708932.7 of Pronobi or Pronobi's Those described in the public document WO 2018 / 224509 related to instant technology, the entire contents of all the above three documents are incorporated herein by reference. If the powder is not in an instant microbial composition, it may be suitable for adding to food (e.g., yogurt) or beverage (e.g., water or milk) before ingestion.
[0079] When the composition is in the form of powder, the composition is usually filled in a sealed container, and the container provides oxygen and moisture barrier to protect and maintain the vigor of bacteria in the composition. Therefore, when the composition is in the form of powder, the composition is preferably packaged in a sealed aluminum foil rod, wherein each rod comprises a composition of a dosage, that is, a dosage of bacteria. The limiting examples of suitable container comprises rod, bag, pouch or capsule. In a preferred embodiment, the container is aluminum foil or polyethylene rod sealed by welding. Rod is usually configured to be easy to tear. Rod can have a tear notch.
[0080] The composition according to the present invention can be formulated into a controlled release solid dosage form, such as any of the controlled release solid dosage forms described in WO 03 / 026687 and U.S. Patent Nos. 8,007,777 and 8,540,980, the entire contents of which are incorporated herein by reference. The composition can be formulated into a layered dosage form, such as a layered dosage form of Probi comprising any of the layered dosage forms described in WO 2016 / 003870. technology, the entire contents of which are incorporated herein by reference.
[0081] Tablets can be made by compression or molding, optionally with one or more auxiliary ingredients. Compressed tablets can be prepared by compressing (e.g., freeze-dried) at least one probiotic strain in a free-flowing form (such as powder or granules) in a suitable machine, optionally mixed with a binder (e.g., polyvinylpyrrolidone, gelatin, hydroxypropyl methylcellulose), a lubricant, an inert diluent, a preservative, a disintegrant (e.g., sodium starch glycolate, cross-linked polyvinylpyrrolidone, cross-linked sodium carboxymethylcellulose), a surfactant or a dispersant. Molded tablets can be prepared by molding a mixture of a powdered compound moistened with an inert liquid diluent in a suitable machine. Tablets can be optionally coated or scored, and can be formulated so that slow or controlled release of active ingredients therein is provided using, for example, different proportions of hydroxypropyl methylcellulose to provide a desired release profile.
[0082] Treatment
[0083] The present invention also provides a method for reducing and / or preventing at least one harmful effect of acute psychosocial stress in a human, wherein the method comprises treating the human by administering to the human an effective amount of at least one Lactobacillus strain or a composition thereof.
[0084] In particular, the method of treatment comprises the above-mentioned method of use, which is at least one strain according to the above-mentioned aspects of the invention.
[0085] "Treatment", "treating" or "treatment" include the meaning that the disease or condition being treated is improved, reduced in severity, eliminated, no longer occurs, prevented from further occurrence, delayed and / or stopped. The term "treat", "treating" or "treatment" also includes the meaning of delaying, preventing, reducing severity and / or eliminating one or more symptoms, effects, indications and / or other markers associated with a given disease or condition. When one of these terms is used in the context of a disease or condition, such treatment is generally performed after the disease or condition manifests. It should also be understood that such terms can include the meaning that the disease or condition remains in its current state and does not get worse or develop further.
[0086] The person treated by the method according to the invention may be any of the persons given above in relation to the earlier aspects of the invention. For example, the person may be a man or a woman, and may be a teenager (12-17 years old), a young adult (18-30 years old) or an adult over 30, 40, 50, 60, 70 or 80 years old.
[0087] Administration according to the method of the invention may comprise oral, buccal or sublingual administration as described above in relation to the first aspect of the invention.
[0088] The administration according to the method of the present invention may comprise at least one, two, three, four, five, six or seven days once or at least once a week, twice, three, four, five, six or seven administrations. Preferably, administration is performed at least once a day. Administration according to the method of the present invention may comprise repeated administration for at least one, two, three, four, five or six days, or at least one, two, three or four weeks. Preferably, repeated administration is performed at least once a day for at least 7 days, for example at least one week, preferably at least two weeks, more preferably at least three weeks, and most preferably at least four weeks.
[0089] According to the invention, the application of the method according to the invention is preferably about 1×10 6 To about 1×10 14 CFU / unit dose, preferably about 1×10 8 To about 1×10 12 CFU / unit dose, more preferably about 1×10 9 To about 1×10 11 CFU / unit dose, and most preferably about 1×10 10 CFU / unit dose. Administration according to the methods of the present invention preferably results in an effective dose of about 1×10 6 To about 1×10 14 CFU / unit dose, preferably about 1×10 8To about 1×10 12 CFU / unit dose, more preferably about 1×10 9 To about 1×10 11 CFU / unit dose, and most preferably about 1×10 10 CFU / unit dose. Preferably, each subject is administered at least one unit dose per day, for example one unit dose per day. Thus, administration according to the method of the present invention preferably results in a daily dose of about 1×10 6 To about 1×10 14 CFU / day, preferably about 1×10 8 To about 1×10 12 CFU / day, more preferably about 1×10 9 To about 1×10 11 CFU / day, and most preferably about 1×10 10 CFU / day.
[0090] It should be understood that the preferred daily dose can also be achieved by administering more than one sub-dose, for example, by administering a unit dose comprising half of the preferred daily dose twice a day. Therefore, the preferred range of effective doses can also represent the preferred daily dose to be achieved at any practical unit dose.
[0091] The subject may be instructed to consume a therapeutically effective amount of at least one strain according to the invention or a composition according to the first aspect of the invention together with water, another aqueous solvent or a food product such as yoghurt.
[0092] It should be understood that the method according to the invention should preferably be performed before the onset of acute psychosocial stress, so that the at least one strain according to the invention can have the effect of reducing and / or preventing at least one harmful effect of acute psychosocial stress caused by a subsequent acute psychosocial stressor. Thus, preferably the administration of the at least one strain according to the invention starts at least 1, 2, 3, 4, 5 or 6 days before the onset of acute psychosocial stress, more preferably at least 1, 2, 3 or 4 weeks before the onset of acute psychosocial stress.
[0093] In a preferred embodiment according to the present invention, a method for reducing and / or preventing at least one harmful effect of acute psychosocial stress in a human comprises administering to the human 10 10 CFU of at least one strain according to the invention or a combination thereof for at least 30 days.
[0094] The treatment methods according to the invention are effective in treating, preventing or reducing at least one symptom of a disease, disorder or condition by reducing and / or preventing at least one deleterious effect of acute psychosocial stress in humans. In particular, the treatment methods according to the invention are effective in treating, preventing or reducing at least one symptom of one or more diseases, disorders or conditions selected from cancer, chemotherapy-induced peripheral neuropathy (CIPN), diabetic retinopathy (DR), inflammatory diseases, cardiovascular diseases, inflammatory bowel disease (IBD), irritable bowel syndrome (IBS), ulcerative colitis and Crohn's disease by reducing and / or preventing elevated levels of soluble fractalkine in plasma as a deleterious effect of acute psychosocial stress in humans. In such methods according to the invention, preferably, the deleterious effect of acute psychosocial stress is elevated levels of soluble fractalkine, particularly in plasma.
[0095] Use in methods
[0096] Another aspect of the present invention provides the use of a composition comprising at least one strain according to the present invention or a composition thereof in a method for reducing and / or preventing at least one harmful effect of acute psychosocial stress in a human. In particular, the method is a method according to the above-mentioned method of the present invention.
[0097] The listing or discussion of an apparently prior-published document in this specification should not necessarily be taken as an admission that the document is part of the state of the art or is common general knowledge.
[0098] The present invention will now be described in more detail with reference to the following examples and accompanying drawings. BRIEF DESCRIPTION OF THE DRAWINGS
[0099] Figure 1 The change in cortisol level ln (nmol / L) after the TSST test is shown. LPHEAL9 is a solid line; placebo is a dashed line. The dashed line at zero represents the level in the first sample before the TSST challenge (baseline), and each time point represents the change from this baseline reading: PREP = the second sample before the TSST challenge; v-TSST = directly after the TSST challenge; R+10, R+20, R+30, R+40, R+60 = 10, 20, 30, 40 and 60 minutes within the recovery phase after the TSST challenge.
[0100] Figure 2 The change in fractalkine level sqrt (pg / mL) after TSST test is shown. The line and x-axis are similar to Figure 1 same.
[0101] Figure 3Shown are changes in soluble CD163 levels (log10 [ng / mL]) after TSST testing. Lines and x-axis are similar to Figure 1 Same, except the results for R+60 are not shown.
[0102] Figure 4 Shown are changes in fractalkine levels (pg / mL) following TSST testing, with two-way comparisons of: (1) subjects with SMBQ values ≥ 3.75 (chronic stress, HS) on the test day versus subjects with SMBQ values < 3.75 (low stress, LS) on the test day, and (2) subjects in the "active" (Lactobacillus plantarum DSM 15312 pre-treated) group versus subjects in the "placebo" control group. Zero on the y-axis represents the level in the first sample before the TSST challenge (baseline), and each time point represents the change from this baseline reading: 0 = v-TSST (directly after TSST challenge); 10, 20, 30, 40, 60 = 10, 20, 30, 40, and 60 minutes after TSST challenge within the recovery phase.
[0103] Figure 5 Shown are the changes in soluble CD163 levels (ng / mL) after TSST testing. Comparison and graphical representation details with Figure 4 same.
[0104] Figure 6 Shows the changes in cortisol levels (nmol / L) after the TSST test. Comparison and graphical representation details with Figure 4 same. DETAILED DESCRIPTION
[0105] Exemplary Dosage Forms
[0106] In addition to the formulations mentioned above (and incorporated herein by reference), the following examples illustrate pharmaceutical and other formulations according to the present invention.
[0107] Example A: Tablets
[0108]
[0109] Tablets are prepared from the above ingredients by wet granulation followed by compression.
[0110] Example B: Tablet Formulation
[0111] The following formulations A and B were prepared by wet granulating the ingredients with povidone solution, followed by addition of magnesium stearate and compression.
[0112] Preparation A
[0113]
[0114] Preparation B
[0115]
[0116] Preparation C
[0117]
[0118] The following formulations D and E were prepared by direct compression of the mixed ingredients. The lactose used in formulation E was of direction compression type.
[0119] Preparation D
[0120] Lactobacillus strain 1×10 10 CFU
[0121] Pregelatinized starch NF15 150mg
[0122] Preparation E
[0123] Lactobacillus strain 1×10 10 CFU
[0124] Lactose 150mg
[0125] 100mg
[0126] Formulation F (controlled release formulation )
[0127] The formulation was prepared by wet granulating the ingredients (ingredients below) with povidone solution, followed by addition of magnesium stearate and compression.
[0128]
[0129] Release occurs over a period of approximately 6-8 hours and is complete after 12 hours.
[0130] Example C: Capsule Formulation
[0131] Preparation A
[0132] The capsule formulation was prepared by mixing the ingredients of Formulation D in Example B above and filling into two-section hard gelatin capsules. Formulation B (see below) was prepared in a similar manner.
[0133] Preparation B
[0134]
[0135] Preparation C
[0136] (a) Lactobacillus strain 1×10 10 CFU
[0137] (b) Polyethylene glycol 4000BP 350 mg
[0138] Capsules were prepared by: melting polyethylene glycol 4000BP; dispersing the Lactobacillus strain in the melt; and filling the melt into two-section hard gelatin capsules.
[0139] Preparation D (controlled release capsules )
[0140] The following controlled release capsule formulation was prepared by extruding ingredients a, b and c using an extruder, and then spheronizing and drying the extrudate. The dried granules were then coated with a release-controlling film (d) and filled into a two-piece hard gelatin capsule.
[0141]
[0142] Example D: Powder Formulation
[0143] Preparation A (fast-melting microbial composition)
[0144]
[0145] Preparation B (fast-melting microbial composition)
[0146]
[0147] Experimental Example 1
[0148] introduce
[0149] Prolonged stress (chronic stress) and stress-related health problems are a concern in many post-industrial countries as it affects personal well-being, the healthcare system and causes sickness absence. To further understand stress-related health problems, the Trier Social Stress Test (TSST) is a widely used tool to induce psychosocial stress in a laboratory setting (Kirschbaum et al., 1993, Neuropsychobiology, 28(1-2): 76-81).
[0150] The aim of this study was to investigate how Lactobacillus strains affect stress markers, gut health, and inflammation when high-stress people (those with chronic stress) consume a study product four weeks before exposure to an acute stress situation (TSST) in a virtual reality laboratory at the Department of Design Science (Ingvar Kamprad Design Center, Faculty of Engineering [LTH], Lund University, Sweden).
[0151] Target
[0152] Main Objectives
[0153] Evaluation of the intake of Lactobacillus plantarum DSM 15312 (HEAL 9 TM ) can counteract the elevated serum cortisol levels in chronically stressed subjects exposed to acute stress (TSST).
[0154] Secondary Objectives
[0155] Evaluation of the intake of Lactobacillus plantarum DSM 15312 (HEAL 9 TM ) can reduce increases in interleukin-6 and other inflammatory markers in chronically stressed subjects exposed to acute stress (TSST);
[0156] Evaluation of the intake of Lactobacillus plantarum DSM 15312 (HEAL 9 TM ) affects intestinal (zonulin) permeability in chronically stressed subjects exposed to acute stress (TSST);
[0157] Evaluation of the intake of Lactobacillus plantarum DSM 15312 (HEAL 9 TM ) affects physiological data such as pulse and heart rate variability in chronically stressed subjects exposed to acute stress (TSST);
[0158] To assess changes in abdominal pain, flatulence, and bloating over time (4 weeks and before and after TSST, respectively);
[0159] The frequency of adverse events (AEs) was collected during the study.
[0160] Investigation plan
[0161] Overall study design
[0162] The study was a prospective, double-blind, placebo-controlled, parallel, single-center study conducted in healthy adults (19-35 years) with or without chronic stress. The study duration was 6 weeks and consisted of two phases:
[0163] Phase 1: Run-in for two weeks. No probiotic products are taken.
[0164] Phase 2: Intake of Lactobacillus plantarum DSM 15312 (HEAL 9 TM ) or placebo for four weeks. TSST challenge was performed on day 30±3.
[0165] Therefore, after a two-week run-in period, subjects were randomly assigned to take either a placebo capsule or a capsule containing Lactobacillus plantarum DSM15312 (HEAL 9 TM ) capsules once a day for 30 days. TSST challenge was performed on day 30±3.
[0166] Selection of study population
[0167] Seventy men and women with high perceived stress were recruited.
[0168] To make the results as comparable as possible, the recruited women underwent the TSST during the luteal phase of the menstrual cycle when possible. Women were asked whether they used contraception.
[0169] Inclusion criteria
[0170] The subjects met the following criteria:
[0171] 1.19-35 years old;
[0172] 2. Shirom-Melamed Burnout Questionnaire (SMBQ) score ≥ 3.75;
[0173] 3. Understand spoken and written Swedish;
[0174] 4. Written informed consent related to study inclusion and receipt of serial number and study product (active or placebo);
[0175] 5. No ingestion of probiotic products during the two weeks prior to the start of study product introduction or throughout the ongoing study.
[0176] Exclusion criteria
[0177] The subject does not meet any of the following criteria:
[0178] 1. BMI>30;
[0179] 2. Pregnancy;
[0180] 3. Taking antibiotics during the study or three months before the introduction of the study product;
[0181] 4. Previous or current contact with health care due to stress-related problems;
[0182] 5. Known physical (diabetes, lung or cardiovascular disease, celiac disease, thyroid problems, gastrointestinal disease) or mental illness;
[0183] 6. Taking psychotropic drugs, beta-blockers, asthma or rheumatoid drugs, steroid drugs or creams containing cortisone.
[0184] The exclusion criteria during the study were
[0185] 1. Treat with antibiotics;
[0186] 2. The subject is unable to come on the day of the test and cannot book a new day;
[0187] 3. Adverse event - subject does not want to continue.
[0188] Dietary regulations
[0189] During their participation in the study, all subjects were instructed to follow certain dietary rules that involved not consuming other products containing probiotics. A list of products that could not be consumed was provided to the study participants.
[0190] treat
[0191] Administration of treatment
[0192] All capsules required for one period were distributed at Visit 1. Remaining capsules were collected and counted. The study product was packaged in external packaging and labeled by Probi personnel not involved in the study.
[0193] Research the identity of your product
[0194] The products studied included a concentration of 10 10 cfu / capsule of freeze-dried Lactobacillus plantarum DSM 15312 (HEAL 9 TM ) capsules or placebo capsules that did not contain bacteria. The fillers used in the capsules were corn starch and magnesium stearate. Both the probiotic and placebo products were white powders with similar appearance, texture, and taste. The probiotic mixture contained trace amounts of soy. The study product was taken once daily in association with breakfast by placing the capsule in the mouth and chewing it.
[0195] Methods of assigning subjects to treatment groups
[0196] The study product was prepared in labeled packages of 40 capsules per subject and labeled according to the corresponding randomization list (701, 702, ..). The investigator provided the study product to the subjects in the order of random assignment.
[0197] Blind
[0198] The study was double-blind, and the subjects, investigators, and ProBi personnel involved in the study did not know which product was distributed to each subject. Code breaking was allowed in emergency situations, but the blinding was not broken during the study.
[0199] Previous and concomitant medications
[0200] Medication use was permitted during the study and was recorded in the study diary.
[0201] Treatment compliance
[0202] At the end of the study, participants were asked to hand in the remaining capsules, which were counted to verify that the correct number of capsules had been ingested. Participants were also required to record the intake of the study product in a study diary. Per-protocol analyses were performed for subjects who took more than 80% of the study product.
[0203] Efficacy and safety variables
[0204] Research process chart
[0205] The activities performed at each visit are shown in the study flow chart ( Table 1 ).
[0206] Table 1: Investigator Assessment Timeline
[0207]
[0208] effect
[0209] Primary End Point
[0210] The primary endpoint was to evaluate the effect of Lactobacillus plantarum DSM 15312 (HEAL 9 TM ) can counteract elevated serum cortisol levels in chronically stressed subjects exposed to an acute stressor (TSST). Cortisol was measured eight times at visit 2; twice before the TSST challenge (baseline, preparation), directly after the challenge (R+0), and five times during the recovery phase (R+10, R+20, R+30, R+40, R+60).
[0211] Secondary End Points
[0212] Shirom-Melamed Burnout Questionnaire (SMBQ)
[0213] The SMBQ was measured before the TSST challenge during the recruitment phase and at the end of the intervention (Visit 2, Day 28).
[0214] Heart rate (HR) and high frequency heart rate variability (HF-HRV)
[0215] Heart rate (HR) and high-frequency heart rate variability (HF-HRV) were measured during the TSST challenge at visit 2. Measurements were performed for 5 min in each of the baseline, preparation, speech, and math conditions and in four subsequent recovery periods (R+10, … R+40), i.e., 8 conditions.
[0216] Intestinal Permeability (Zonulin)
[0217] Serum zonulin was measured three times at Visit 2; once before TSST challenge (baseline) and twice during the recovery phase (R+10, R+60).
[0218] Inflammatory markers
[0219] Different inflammatory markers, such as CRP and IL-6, were measured in plasma eight times at visit 2; twice before TSST challenge (baseline, preparation), directly after challenge (R+0), and five times during the recovery phase (R+10, R+20, R+30, R+40, R+60).
[0220] Intestinal function
[0221] Basic questions about bowel function were asked at Visit 1. Bowel function was further assessed three times by filling out a visual analog (VAS) scale (0-10) for abdominal pain, gas, and bloating; once at Visit 1 and twice at Visit 2 (before and after the TSST challenge).
[0222] Trier Social Stress Test (TSST)
[0223] The Trier Social Stress Test (TSST) is a widely used protocol for inducing social stress in laboratory settings (Kirschbaum et al., 1993, supra). Briefly, test participants are asked to give a speech and perform an arithmetic task in front of a committee. The committee consists of three actors who do not show any emotional response to the test participants, making the situation highly stressful. et al. (2010, Psychoneuroendocrinology, 35(9):1397-1403) conducted the TSST in a virtual reality environment (V-TSST) and in the afternoon (1:00 to 5:00 p.m.) to avoid diurnal fluctuations in cortisol. TMThe system was created using a computer vision system (CAVE Automated Virtual Environment, Electronic Visualization Laboratory, University of Illinois) with three rear-projection walls (4m × 3m) and a floor projection. For 3D vision, a passive stereoscope was used. Two virtual rooms were created using Autodesk1 3ds Max1 9 and EON Professional 5.5 (EON Reality, Inc.) software: The waiting room consisted of a table, pictures on the wall, two chairs, a small table, and a door on the opposite wall. Behind the door there was a room where a woman and two men (designed by aXYZ design) formed a committee ( et al., 2010, supra; et al., 2011, Presence, 20(4):325-336). According to the standard TSST protocol (Kirschbaum et al., 1993, supra), the committee's comments and instructions were given via pre-recorded voices. The comments were activated by the test leader using a remote keyboard that was invisible to the test participant. For example, if the participant had difficulty continuing his speech, the middle-aged man would tell him "You still have time," or "Please continue and I'll tell you when your time is up." The V-TSST has been shown to elicit reliable cortisol and cardiovascular responses in healthy women and men (Fich et al., 2014, Physiol Behav, 135:91-97; et al., 2010, supra; et al., 2015, Physiol Behav, 151: 327-337).
[0224] Shirom-Melamed Burnout Questionnaire (SMBQ)
[0225] The SMBQ contains 22 items that assess four dimensions of burnout syndrome: ennui, tension, listlessness, and cognitive fatigue (Melamed et al., 1992, Behav Med, 18(2):53-60). The SMBQ global score is represented by the average of the four dimensions. The Swedish translation has been previously validated by Grossi et al. (2003, J Psychosom Res, 55(4):309-16) and Lundgren-Nilsson et al. (2012, BMC Public Health, 12:1). The SMBQ was measured at inclusion and on the day of the VSST experiment. Spielberger State and Trait Anxiety Inventory (STAI)
[0226] The STAI-State Scale (STAI-S) was assessed before baseline and after 60 minutes of recovery to estimate participants' experience of the V-TSST. At the second assessment, the instructions changed slightly from "Answer questions about how you feel now" to "Answer questions based on how you felt during the V-TSST."
[0227] Heart rate (HR)
[0228] Electrocardiogram (ECG) and respiration were recorded at 1 kHz using an ML866 Power Lab data acquisition system and analyzed using its software Chart5 (ADInstruments Pty Ltd.) and MATLAB (MathWorks, Inc., Natick, MA). ECG was assessed using disposable electrodes (Lead II Einthoven), and respiration was assessed using a strain gauge on the chest. 5-min evaluation of heart rate (HR) ( et al., 2010, supra). The same applies to the following HF-HRV.
[0229] High Frequency Heart Rate Variability (HF-HRV)
[0230] RR intervals were converted to tachograms (ms) and linearly interpolated at 4 Hz. The data were further linearly detrended and high-pass filtered (second-order Butterworth filter, 0.10 Hz) to eliminate fluctuations below the respiratory rate. For each 5-minute sequence, the HRV intensity spectrum was calculated for 17 segments of 128 points (32 seconds) and 50% overlap using a fast Fourier transform (1024 points) after applying multiple peak matching windows. The peak matching multi-window (PM MW) method optimizes the mean square error of the spectrum estimation when the expected spectrum includes peaks (Hansson, 1999, IEEE Trans Signal Processing 47:1141-1146; Hansson and Salomonsson, 1997, IEEE Trans Signal Processing 45:778-781)). The PMMW method has been shown to provide reliable results for the HRV spectrum (Hansson-Sandsten and 2007,Transactions Biomed Engineering,54:1770-1779); Hansson and 2006, Medical Engineering & Physics, 28: 749-761). The integration of the intensity spectrum was studied in the high frequency (HF) region (0.12–0.4 Hz) associated with respiration (Berntson et al., 1997, Psychophysiology, 34: 623-648). The data were logarithmically transformed (ln) to approximate a normal distribution. Respiratory measurements were used to ensure that the respiratory frequency was within the HF range.
[0231] Biochemical analysis
[0232] To verify the intake of active study product compared with placebo, oral lactobacilli were analyzed. Saliva of test subjects was collected at visit 1 and visit 2. Saliva and 2x Hogness freezing medium (9.8mM K2HPO4, 2.9mM KH2PO4, 10.2mM C6H5Na3O7·2(H2O), 2.0mM MgSO4·7(H2O), 24.2% glycerol) were mixed in equal parts, then frozen and stored at -80°C.
[0233] Peripheral venous blood was collected eight times; twice before TSST challenge (baseline, preparation), directly after challenge (TSST; speech + math), and five times during the recovery phase (rest + 10min, R + 20, R + 30, R + 40, and R + 60). Serum and plasma (plasma for analysis of cortisol and CRP) were separated at 2000 x g for 10 min at room temperature. Plasma for cytokine analysis was kept in an ice bath and separated at 2000 x g for 10 min at 4 °C (Eppendorf Centrifuge 5702R) within 30 min of sampling, using EDTA as anticoagulant.
[0234] Saliva, serum, and plasma samples were frozen on dry ice and then stored at −80°C until further analysis. The cortisol concentration in serum was determined by a one-step competitive assay based on the electrochemiluminescence immunoassay (ECLI) detection technology of ruthenium derivatives and was provided by Labmedicin (University and Regional Laboratories in Skåne, Sweden). Zonulin was analyzed in serum using an ELISA method (K5601, Immundiagnostik AG, Bensheim, Germany) with a detection range of 0.25-64 ng / ml. Cytokines Fractalkine, IFN-γ, IL-10, IL-1β, IL-6, IL-8, TNF-α were analyzed in plasma using a multiplex technique (U-PLEX Human 7-plex [Fractalkine, IFN-γ, IL-10, IL-1β, IL-6, IL-8, TNF-α], MesoScale Discovery, Rockville MD, US) with detection limits of 102 pg / mL, 1.7 pg / mL, 0.14 pg / μl, 0.15 pg / mL, 0.33 pg / mL, 0.15 pg / mL, and 0.51 pg / mL, respectively. Soluble CD163 in plasma was analyzed using the ELISA method (DY1607, R&D Systems, Minneapolis, US).
[0235] Security
[0236] Adverse Event Reporting An adverse event (AE) is any undesirable medical occurrence in a patient or clinical investigation subject administered a medicinal product that is not necessarily causally related to the treatment. Thus, an AE may be any unfavorable and unexpected sign (including abnormal laboratory findings), symptom or disease temporally associated with the use of a medicinal (investigational) product.
[0237] A serious adverse event (SAE) is any undesirable medical occurrence at any dose that:
[0238] - Causes death;
[0239] - Life-threatening (the term 'life-threatening' in the definition of 'serious' refers to events in which the patient is at risk of death at the time of the event;
[0240] It does not refer to an event that, if more severe, could have resulted in death);
[0241] - Requires hospitalization or prolongation of existing hospitalization;
[0242] - Causes persistent or severe disability / incapacity;
[0243] - is a congenital anomaly / birth defect;
[0244] - is a significant medical event requiring intervention to prevent one of the above events.
[0245] Adverse event causality
[0246] The investigator should attempt to assess, as a whole, the causal relationship of the AE to the investigational product. The following categories are used: Probable: A clear temporal relationship between the AE and administration of the investigational product is evident. The relationship between the AE and the investigational product is known or expected. Symptoms resolve or abate after discontinuation of the investigational product or reduction of its dose. The adverse reaction cannot be explained by the patient's clinical condition.
[0247] Possible: A clear temporal relationship between the AE and drug administration. The relationship between the AE and drug is known or expected. Many other factors may also explain the adverse reaction.
[0248] Unlikely: A temporal relationship between the AE and study product administration is unlikely. The adverse reaction should be explained by other factors,
[0249] However, a relationship with the research product cannot be absolutely ruled out.
[0250] Testing, reporting and liability
[0251] The obligation to report AEs begins with the enrollment of a subject in a study. The investigator is obliged to record all AEs in the subject's clinical record, describing the date of onset and date of discontinuation.
[0252] Dataset to be analyzed
[0253] All properly enrolled and randomized subjects who underwent the TSST challenge were included in the Full Analysis Set (FAS), and all randomized subjects who took at least one capsule of the study product were included in the Safety Set.
[0254] In order for subjects to be included in the Per-Protocol Set (PPS), they had to meet the following criteria:
[0255] TSST challenge was performed on day 30 ± 3 of the second phase;
[0256] At least 80% of the research product has been consumed;
[0257] · Not taking antibiotics during the study period;
[0258] No other probiotic products were taken after the start of the study (small amounts were allowed).
[0259] Summary Statistics
[0260] In general, data are summarized using summary statistics. The number of observations, mean, standard deviation, median, quartiles, minimum and maximum values are presented (in the statistical analysis report, M 2018).
[0261] Summary statistics are presented by group.
[0262] Efficacy analysis
[0263] Primary efficacy analysis
[0264] The primary endpoint was to evaluate the effect of Lactobacillus plantarum DSM 15312 (HEAL 9 TM ) can counteract the elevated serum cortisol levels in chronically stressed subjects exposed to acute stress (TSST).
[0265] The null hypothesis was that consumption of Lactobacillus plantarum DSM 15312 (HEAL 9 TM There was no difference in cortisol levels between the group that consumed ) and the group that consumed a placebo.
[0266] An alternative hypothesis is to consume Lactobacillus plantarum DSM 15312 (HEAL 9 TM There was a difference in cortisol levels between the group that consumed ) and the group that consumed a placebo.
[0267] Analyses were performed based on repeated measures ANOVA with condition as repeated factor and intervention (HEAL 9 and placebo) as between-group factor. Therefore, analyses of change over time (condition) were also included. AGE and BMI were used as covariates and entered stepwise. Any covariate that did not contribute significantly to each model was removed and not reported. To meet the assumption of sphericity, a Greenhouse-Geisser correction was performed and the corrected p-values, uncorrected df and ε are reported. Multinomial contrasts were followed up for significant omnibus effects.
[0268] As an exploratory analysis, HEAL 9 and placebo were also compared using a single time point.
[0269] Secondary Efficacy Analyses
[0270] Secondary objectives included evaluating Lactobacillus plantarum DSM 15312 (HEAL 9 TM ) could attenuate increases in zonulin, inflammatory markers, pulse and heart rate in chronically stressed subjects exposed to acute stress (TSST). The same statistical methods as for the primary variables were used.
[0271] Another secondary objective was to evaluate the efficacy of Lactobacillus plantarum DSM 15312 (HEAL 9 TM Changes in abdominal pain, flatulence, and bloating over time after TSST challenge or placebo were analyzed using the Wilcoxon rank-sum test (for comparisons of intervention groups) or the Wilcoxon signed-rank test (for comparisons before and after treatment).
[0272] The correlation between some variables was done by using Spearman rank correlation test.
[0273] Study Patients
[0274] Arrangement of subjects Seventy subjects were included in the study (Table 2). One subject terminated the study before consuming any study product and four excluded subjects did not return their diaries, so safety could not be determined for these subjects. Sixty-five subjects were included in the safety group and 63 subjects were included in the FAS. Of the seven subjects excluded from the FAS, three subjects consumed antibiotics between the time of inclusion and the TSST challenge, two subjects were unable to come on the test day, and one subject reported an adverse event and did not want to continue. Five subjects were excluded for taking the study product for more than 33 days and one subject was excluded for a non-comparable TSST, leaving 57 subjects in the PPS.
[0275] Table 2. Number of subjects included in different datasets.
[0276] Total number of subjects Security Group Full analysis group Groups by Scheme 70 65 63 57
[0277] result
[0278] Demographics and baseline data
[0279] The FAS population consisted of 63 subjects with a mean age of 23.5 years and a mean BMI of 23.4 (Table 3). The PP population consisted of 57 subjects (five subjects were excluded because of an intervention period of more than 33 days and one was excluded because of a delay of approximately 1 hour in the TSST test).
[0280] Table 3. Summary of demographic and other baseline characteristics (mean, range)
[0281]
[0282] Previously taken probiotics
[0283] Before visit 1, few subjects consumed probiotics (4 of 70, 6%).
[0284] Treatment compliance
[0285] Subjects recorded the intake of study product in a diary daily. In addition, the number of capsules dispensed and returned by each subject was recorded at Visit 2. A summary of compliance is presented in Table 4. Compliance was good, ranging from 92% to 107%, so no subject was excluded from the per-protocol analysis due to compliance less than 80%.
[0286] Table 4. Summary of compliance (%, FAS) a
[0287]
[0288] a Calculated as (number of capsules taken / number of days between visit 1 and visit 2)*100.
[0289] Lactobacillus counts in saliva
[0290] At the beginning, before the intervention, 76% of the subjects had detectable levels of Lactobacillus in their saliva. In the group consuming LPHEAL9, Lactobacillus counts in saliva increased significantly, from a median of 7.3 log10 cfu / ml before the intervention to 9.3 log10 cfu / ml after the intervention (Table 5). After four weeks of intake, the Lactobacillus levels in the saliva of this group were significantly increased compared to the placebo group.
[0291] Table 5. Lactobacillus counts in saliva before and after intervention (log 10 cfu / ml)(median, min-max, FAS)
[0292] Before intervention After 4 weeks of intervention change <![CDATA[P-value a within the group]]> LPHEAL9 (n=32) 7.3(<2.9–12.9) 9.3(<2.9–17.6) 2.1(-3.1–12.1) 0.000 Placebo (n=31) 4.6(<2.9–12.2) 5.3(<2.9–13.4) 0(-3.6–3.7) 0.741 <![CDATA[P-value b between groups]]> 0.274 0.000 0.000
[0293] a Wilcoxon signed-rank test. 2-sided.
[0294] b Wilcoxon rank-sum test. 2-sided.
[0295] SMBQ global score and State-Trait Anxiety Inventory (STAI-S)
[0296] At inclusion, all subjects had to be classified as highly stressed (global score ≥ 3.75) according to the SMBQ questionnaire. After the four intervention weeks, the SMBQ global scores were significantly reduced in both groups, but no significant differences between the groups were found at any time point (Table 6). Approximately one-third of the subjects had an SMBQ global score below 3.75 after the intervention and were therefore no longer classified as highly stressed. The global scores of the SMBQ before the intervention were roughly the same as those observed in earlier TSST studies on highly stressed subjects (mean 4.64, Linninge et al., 2018, Biol Psychol, 138: 48-55).
[0297] Table 6. SMBQ global scores before and after intervention (mean, SD)
[0298]
[0299] a Wilcoxon signed-rank test. 2-sided.
[0300] bWilcoxon rank-sum test. 2-sided.
[0301] Lactobacillus plantarum DSM 15312 (HEAL 9 TM Both the induced acute stress effects, as measured by the State-Trait Anxiety Inventory (STAI-S), and the placebo group were correlated with the TSST (p < 0.0001). The scores on the STAI-S before and after the test (40 and 54, respectively) were roughly the same as those observed in earlier studies of the TSST in highly stressed subjects (Linninge et al., 2018, supra).
[0302] Efficacy Results
[0303] Primary efficacy analysis - serum cortisol levels
[0304] There was a main effect of condition (i.e., time point), F(6,342) = 21.42, p < 0.0001, η 2 = 0.27, ∈ = 0.409, indicating that cortisol increased after stress induction and 10 minutes after recovery, and then slowly decreased over time. The linear contrast F 线性 (1,57)=18.72, p<0.0001, η 2 =0.25, secondary contrast F 二次 (1,57)=24.35, p<0.0001, η 2 = 0.30, and cubic contrast F 立方 (1,57)=23.10, p<0.0001, η 2 =0.29, see Figure 1 No other significant effects were found.
[0305] Post hoc analysis of PP subjects with higher post-test cortisol levels than pre-test (77% of subjects, LPHEAL9 n=23, placebo n=21) showed significant increases in cortisol levels in both groups compared to baseline, 0 min, and 10 min post-TSST. For the placebo group, it was also significantly increased at 20 and 30 min compared to pre-test. There were no significant differences between the groups at any time point, but at 10 min post-test, there was a trend toward lower cortisol levels in the LPHEAL9 group compared to the placebo group (p=0.07).
[0306] Secondary Efficacy Analyses - Inflammatory Markers and Zonulin
[0307] Soluble fractalkine in plasma increases and reaches a peak 10 minutes after V-TSST, then gradually decreases over the next 20 minutes (see Figure 2). Afterwards, fractalkine increased again during the rest of the recovery process, F(6,318)=14.21, p<0.0001, η 2 =0.21,∈=0.737,F 线性 (1,53)=7.12、p<0.010、η 2 =0.12, F 立方 (1,53)=39.61, p<0.0001, η 2 =0.43.
[0308] A main effect of group (i.e., treatment group) was found, F(1,53)=9.41, p=0.003, η 2 =0.15. Fractalkine levels increased more in the placebo group compared with baseline and remained above fractalkine levels in the LPHEAL9 group. The condition*group interaction was not significant.
[0309] The group effects seen were also confirmed when comparing individual time points: fractalkine levels were significantly lower in the LPHEAL19 group than in the placebo group at 20 and 60 minutes after testing.
[0310] Soluble CD163 (sCD163) in plasma
[0311] The main effect of condition generally showed that sCD163 values decreased from preparation to the end of the 40-min recovery, F(5,295) = 10.93, p < 0.0001, η 2 =0.16,∈=0.898,F 线性 (1,59)=38.08, p<0.0001, η 2 =0.39(see Figure 3 ).
[0312] The group* condition was also significant, F(5,295)=3.07, p=0.013, η2=0.05, ∈=0.898, F 二次 (1,59) = 12.87, p < 0.001, η2 = 0.18. After baseline, sCD163 values in the placebo group decreased during preparation, then increased and peaked after stress induction. Afterwards, these values gradually decreased as a function of time. sCD163 values in the active group increased during preparation, then decreased during recovery.
[0313] Comparison of individual time points showed that sCD163 levels in the LPHEAL19 group were significantly lower than those in the placebo group at 0, 10, 20, and 60 minutes after testing.
[0314] The results with sCD163 confirm those with fractalkine, as both sCD163 and fractalkine are released by the ADAM-17 protease.
[0315] Plasma IFN-γ
[0316] After an initial small decrease, IFN-γ increased and reached a maximum 10 min after stress induction, after which it decreased below baseline levels during the last 30 min of recovery, F(6,348)=10.66, p<0.0001, η 2 =0.16,∈=0.702,F 二次 (1,58)=4.87, p=0.031, η 2 =0.08, and F 立方 (1,58)=41.40, p<0.0001, η 2 =0.42. No other significant effects were found.
[0317] Plasma IL-1β
[0318] The levels of IL-1β did not change significantly, and no significant differences were found between the groups.
[0319] Plasma IL-10
[0320] No significant effects were found.
[0321] Plasma IL-6
[0322] The results showed that the main effect of condition was significant, F(6,330)=86.74, p<0.0001, η 2 =0.61,∈=0.502,F 线性 (1,55)=173.70, p<0.0001, η 2 = 0.76, and F 立方 (1,55)=19.77, p<0.0001, η 2 =0.26. After preparation, IL-6 began to increase sharply. After 10 minutes of recovery, it continued to increase, but less steeply, until 40 minutes of recovery, after which it increased more steeply again. No other significant effects were found.
[0323] Plasma IL-8
[0324] A main effect of condition was found, F(6,354)=9.92, p<0.0001, η 2=0.14, ∈ =0.831. During the preparatory condition, IL-8 levels were slightly lower than during the baseline period. Then IL-8 levels increased during the V-TSST, then decreased until 30 minutes of recovery, and then increased a second time after 40 minutes of recovery, F 二次 (1,59)=14.79, p<0.001, η 2 = 0.20, and F 立方 (1,59)=16.35, p<0.0001, η 2 =0.22.
[0325] The main effect of group was also significant, F(1,59)=4.26, p=0.043, η 2 =0.07. IL-8 levels increased more in the LPHEAL19 group than in the placebo group and remained elevated for the rest of the recovery period. The condition*group interaction was not significant.
[0326] Plasma TNF-α
[0327] The main effect of condition was significant, F(6,348)=18.38, p<0.0001, η 2 =0.24, ∈ =0.819. After a small decrease in preparation and V-TSST, TNF-α levels increased and peaked after 10 minutes of recovery. Levels then gradually decreased until 40 minutes of recovery when a rapid increase occurred, F 线性 (1,58)=8.32, p=0.005, eta 2 =0.13, F 二次 (1,58)=7.96, p=0.007, eta 2 =0.12, F 立方 (1,58)=64.61, p<0.0001, η 2 =0.53. No other significant effects were found.
[0328] Serum Zonulin
[0329] No significant effects were found.
[0330] Secondary efficacy analyses - pulse and heart rate variability
[0331] Pulse rate (HR)
[0332] The main effect of condition was significant, F(6,330)=107.49, P<0.0001, η 2 =0.66,ε=.44,F 线性 =(1,55)=157.37, P<0.0001, η 2 =0.74, F 二次(1,55)=18.94, p<0.0001, η 2 =.26, F 立方 (1,55)=115.22, p<0.0001, η 2 = 0.68. After baseline, HR increased and peaked at speech, then decreased and remained at approximately baseline levels.
[0333] Heart rate variability (HF-HRV)
[0334] HF-HRV decreased during preparation, speech, and mathematics, then increased during the first 10-minute recovery period. It then decreased slightly during the rest of the recovery period. F(3,330)=6.12, p=0.001, η 2 =0.10,∈=0.46,F 线性 (1,55)=8.09, p=0.006, η2=0.13, and F 二次 (1,55)=13.32, p=0.001, η 2 =0.20.
[0335] Secondary efficacy analysis - intestinal function
[0336] Abdominal pain, flatulence, and bloating were assessed three times: before ingestion of the study product, at the end of the intervention period before the TSST test, and after the TSST test. No significant differences in bowel function were found between the groups.
[0337] Safety Assessment
[0338] Gastrointestinal adverse events were reported by 21 subjects (32%). Most events were mild and possibly related to ingestion of the study product (Table 7). There were no differences in reported GI adverse events between groups; 16 events were reported by 9 subjects in the LPHEAL9 group and 20 events were reported by 12 subjects in the placebo group. The most common GI adverse event was abdominal pain (8 events), followed by bloating (7 events) and stomach rumbling and nausea (5 events each).
[0339] Just after the TSST, one subject in the placebo group experienced a serious adverse event related to stress. The subject fainted, fell, and dislocated his shoulder. The subject had to go to the hospital for help to put his shoulder back in place. The subject had also experienced this one month prior but had not reported this to the investigators during the inclusion period. This event is unlikely to be related to ingestion of the study product.
[0340] Table 7. Gastrointestinal adverse events reported during the study (safety group)
[0341]
[0342]
[0343] Discussion and overall conclusions
[0344] In individuals with chronic stress before the test, the onset of acute psychosocial stress caused by the TSST resulted in a higher and longer release of cortisol in the placebo group than in the lactobacillus strain treatment group. Therefore, pretreatment with a lactobacillus strain (Lactobacillus plantarum DSM 15312) reduced the release of cortisol due to acute psychosocial stress compared to the placebo control. It was determined for the first time that the onset of acute psychosocial stress resulted in the release of fractalkine. In chronically stressed individuals who suffered from an acute psychosocial stress episode (TSST), the release of fractalkine was observed at 10 minutes of the recovery phase, and further release was then observed at 60 minutes of the recovery phase. Pretreatment with a lactobacillus strain (Lactobacillus plantarum DSM 15312) resulted in a significant reduction in fractalkine levels (release of soluble fractalkine) compared to the placebo control.
[0345] In individuals with chronic stress, an episode of acute psychosocial stress induced by the TSST resulted in an increase in plasma levels of soluble CD163 compared to baseline in the placebo control group. However, pretreatment with a Lactobacillus strain (Lactobacillus plantarum DSM 15312) during and after the test prevented this increase. Therefore, the results for sCD163 appear to confirm the effect of the Lactobacillus strain (Lactobacillus plantarum DSM 15312) on the release of fractalkine induced by acute psychosocial stress, as both fractalkine and sCD163 are released by the ADAM17 protease.
[0346] Therefore, the administration of lactobacilli, in particular Lactobacillus plantarum DSM 15312 (HEAL 9 TM ), which can be used to reduce and / or prevent at least one harmful effect of acute psychosocial stress in humans, particularly increased levels of plasma cortisol, soluble fractalkine and CD163.
[0347] Experimental Example 2
[0348] introduce
[0349] To determine whether the positive effects of Lactobacillus treatment observed in Experimental Example 1 were limited to acute psychosocial stress in the context of chronic stress or whether they could be expected to benefit all individuals experiencing acute psychosocial stress, we performed further analyses of data from individuals in Experimental Example 1 who were not defined as having chronic stress on the day of the TSST test.
[0350] method All details of the methods were in accordance with Experimental Example 1. However, in Experimental Example 1, a mixed population of subjects who were either low or high stress on the day of the TSST test was included. Experimental Example 2 included separate analyses of individuals in Example 1 who had an SMBQ score of 3.75 or higher on the day of the TSST test (such individuals were designated as "high stress" [HS] subjects) and individuals in Example 1 who had an SMBQ score of less than 3.75 on the day of the TSST test (such individuals were designated as "low stress" [LS] subjects).
[0351] result
[0352] On the day of testing, the active ingredient (Lactobacillus plantarum DSM 15312 [HEAL 9 TM ]) group and 12 subjects in the placebo group had SMBQ scores below 3.75 and were designated as LS subjects.
[0353] The levels of fractalkine, soluble CD163, and Cortisol in HS and LS subjects only are shown in Tables 8-10 below. Soluble fractalkine in plasma
[0354] There were no significant differences between chronically stressed subjects (SMBQ values ≥ 3.75; n = 42) and LS subjects (SMBQ values < 3.75; n = 21) (combined treatment groups) at any time point. At 30 minutes post-test, fractalkine levels were significantly reduced in LS subjects taking LP HEAL9 compared to corresponding subjects in the placebo group. Figure 4 and Table 8.
[0355] Table 8. Fractalkine Levels (pg / mL) in Plasma after TSST Test (Mean Change from Pretest); HS / LS Subjects
[0356] Time after TSST test LP HEAL9 Group Placebo group <![CDATA[P-value 1 , between groups]]> 0min -107 / -225 -35 / -91.7 0.079 / 0.193 +10min 63 / 20 400 / 125 0.397 / 0.247 +20min -91 / -208 136 / 41 0.126 / 0.201 +30min -241 / -497 -166 / -169 0.487 / 0.028 +40min -317 / -398 -143 / -142 0.383 / 0.227 +60min -178 / -237 178 / 134 0.060 / 0.227
[0357] 1 Wilcoxon rank sum test
[0358] Soluble CD163 in plasma
[0359] At the last time point, there was a significant difference between chronically stressed subjects (SMBQ values ≥ 3.75) and LS subjects (SMBQ values < 3.75) (-12.30 and 10.81, respectively) (combined treatment groups) (p = 0.021). LS subjects taking LP HEAL9 had significantly lower sCD163 levels at 0 and 10 minutes after testing compared to corresponding subjects in the placebo group. Figure 5 and Table 9.
[0360] Table 9. Soluble CD163 levels (ng / mL) in plasma after TSST test (mean change from pre-test); HS / LS subjects.
[0361] Time after TSST test LP HEAL9 Group Placebo group <![CDATA[P-value 1 , between groups <!-- 28 -->]]> 0min -7.73 / -6.05 23.69 / 17.28 0.010 / 0.028 +10min -9.10 / -3.17 3.46 / 16.28 0.161 / 0.025 +20min -21.14 / -11.50 18.42 / 20.04 0.103 / 0.076 +30min -28.69 / -11.64 -9.59 / -0.93 0.397 / 0.356 +40min -18.40 / -13.30 -4.76 / 0.46 0.604 / 0.155 +60min -21.60 / 6.04 -1.05 / 14.00 0.079 / 0.322
[0362] 1 Wilcoxon rank sum test
[0363] Serum cortisol
[0364] There were no significant differences between chronically stressed subjects (SMBQ values ≥ 3.75; n = 42) and LS subjects (SMBQ values < 3.75; n = 21) (combined treatment groups) at any time point. For LS subjects, there was a significant difference in cortisol between the LP HEAL9 group and the placebo group 10 minutes after testing (p = 0.025). Figure 6 and Table 10.
[0365] Table 10. Cortisol levels (pg / mL) in serum after TSST test (mean change from pre-test); HS / LS subjects.
[0366] Time after TSST test LP HEAL9 Group Placebo group <![CDATA[P-value 1 , between groups]]> 0min 43 / 40 40 / 69 0.343 / 0.241 +10min 36 / 11 39 / 94 0.649 / 0.025 +20min 14 / 24 22 / 63 0.889 / 0.277 +30min -1 / 4 23 / 40 0.854 / 0.058 +40min -6 / 1 9 / 21 0.940 / 0.277 +60min -27 / -20 -15 / 4 0.714 / 0.219
[0367] 1 Wilcoxon rank-sum test.
Claims
1. A method for reducing and / or preventing at least one detrimental effect of acute psychosocial stress in a human, wherein the method comprises treating the human by administering to the human an effective amount of at least one Lactobacillus strain, and wherein the detrimental effect is an increased level of soluble fractalkine.
2. A method for reducing and / or preventing at least one detrimental effect of acute psychosocial stress in a human, wherein the method comprises treating the human by administering to the human an effective amount of at least one Lactobacillus strain, and wherein the at least one detrimental effect is an increased level of soluble fractalkine and at least one further detrimental effect of acute psychosocial stress.
3. The method of claim 2, wherein the at least one further deleterious effect of acute psychosocial stress is selected from one or more of biochemical and / or physiological indicators of stress.
4. The method according to claim 3, wherein the biochemical markers are selected from the group consisting of elevated levels of one or more cytokines, in particular inflammatory cytokines, preferably one or more of Cortisol and / or soluble CD163.
5. The method according to any one of claims 2 to 4, wherein the further deleterious effect is an increase in soluble CD163 levels.
6. The method according to any preceding claim, wherein the increased level of soluble fractalkine is an increased plasma level of soluble fractalkine.
7. A method according to any preceding claim, wherein the person to be treated suffers from chronic stress.
8. The method of claim 7, wherein chronic stress is indicated by a score of 3.75 or higher on the Shirom-Melamed Burnout Questionnaire.
9. The method according to any preceding claim, wherein the effective dose of the at least one Lactobacillus strain is about 1×10 6 About 1×10 14 Colony forming units (CFU).
10. The method of claim 9, wherein the effective dose of the at least one Lactobacillus strain is about 1×10 8 About 1×10 12 CFU.
11. The method of claim 10, wherein the effective dose of the at least one Lactobacillus strain is about 1×10 9 About 1×10 11 CFU.
12. The method of claim 11, wherein the effective dose of the at least one Lactobacillus strain is about 1×10 10 CFU.
13. The method according to any preceding claim, wherein an effective dose of the at least one Lactobacillus strain is administered at least once a day.
14. The method of any preceding claim, wherein the effective dose is administered daily for at least one week.
15. The method of claim 14, wherein the effective dose is administered daily for at least four weeks.
16. The method according to any preceding claim, wherein the at least one Lactobacillus strain is selected from the group consisting of Lactobacillus plantarum, Lactobacillus paracasei, Lactobacillus rhamnosus, Lactobacillus crispatus, Lactobacillus gasseri, Lactobacillus fermentum, Lactobacillus reuteri, Lactobacillus acidophilus, Lactobacillus helveticus, Lactobacillus casei, Lactobacillus salivarius and Lactobacillus johnsonii.
17. The method according to claim 16, wherein the at least one Lactobacillus plantarum strain is selected from the group consisting of Lactobacillus plantarum DSM 15312, Lactobacillus plantarum DSM 15313, Lactobacillus plantarum DSM 15316, Lactobacillus plantarum DSM 6595, Lactobacillus plantarum DSM 9843, Lactobacillus plantarum DSM 32131, Lactobacillus plantarum DSM 17852 and Lactobacillus plantarum DSM 17853.
18. The method according to claim 16 or 17, wherein the at least one Lactobacillus plantarum strain is capable of adhering to the intestinal epithelium and persisting in the intestine.
19. The method according to any one of claims 16 to 18, wherein the at least one Lactobacillus plantarum strain comprises a mannose-specific adhesin.
20. The method according to any one of claims 16 to 19, wherein the at least one Lactobacillus plantarum strain is Lactobacillus plantarum DSM 15312 (HEAL 9 TM ).
21. The method according to any preceding claim, wherein the at least one Lactobacillus strain is administered in the form of a composition comprising at least one carrier material, excipient material and / or diluent material.
22. The method of claim 21, wherein the composition is provided in the form of a solution, suspension, emulsion, tablet, granule, powder, capsule, lozenge, chewing gum or suppository.
23. The method of claim 22, wherein the composition is provided in the form of a capsule.
24. The method of claim 21, wherein the carrier material is a food.
25. At least one Lactobacillus strain for use in a method of reducing and / or preventing at least one deleterious effect of acute psychosocial stress in a human, wherein the method comprises treatment by administering an effective dose of the at least one Lactobacillus strain and wherein the deleterious effect is an increased level of soluble fractalkine.
26. At least one Lactobacillus strain for use in a method of reducing and / or preventing at least one deleterious effect of acute psychosocial stress in a human, wherein the method comprises treatment by administering an effective dose of the at least one Lactobacillus strain and wherein the at least one deleterious effect is an increased level of soluble fractalkine and at least one further deleterious effect of acute psychosocial stress.
27. At least one Lactobacillus strain for use according to claim 25, wherein the at least one further deleterious effect of acute psychosocial stress is selected from one or more biochemical and / or physiological markers of stress, optionally wherein the biochemical markers are selected from increased levels of one or more cytokines, in particular inflammatory cytokines, preferably soluble CD163 or Cortisol.
28. A composition as defined in claim 21 for use in reducing and / or preventing at least one detrimental effect of acute psychosocial stress in a human.
29. The method according to any one of claims 1 to 24, for use in a method of treating, preventing and / or alleviating at least one symptom of cancer, inflammatory diseases, cardiovascular diseases, inflammatory bowel disease, irritable bowel syndrome (IBS), ulcerative colitis and / or Crohn's disease in a human.
30. At least one Lactobacillus probiotic strain for use according to any one of claims 25 to 27, wherein the use is in a method for treating, preventing and / or alleviating at least one symptom of cancer, chemotherapy-induced peripheral neuropathy (CIPN), diabetic retinopathy (DR), inflammatory diseases, cardiovascular diseases, inflammatory bowel disease, irritable bowel syndrome (IBS), ulcerative colitis and / or Crohn's disease in a human.
31. The composition for use according to claim 28, wherein the use is in a method for treating, preventing and / or alleviating at least one symptom of cancer, chemotherapy-induced peripheral neuropathy (CIPN), diabetic retinopathy (DR), inflammatory diseases, cardiovascular diseases, inflammatory bowel disease, irritable bowel syndrome (IBS), ulcerative colitis and / or Crohn's disease in a human.
